| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5df5ae200801690027bd305c84230d0b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_82720f0fe09c6d788db8fde9be2350dc |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2019-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad79d771c062f8e61f9d360a1989846d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5e20aea18885700cc73f86e904dac87
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c784523f2845b4c7b3a2a63d5e57d5a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf7131c5b7b8e0d49aadab224eb4da52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cefeb19ba1eac02dc0262fa5373b8765 |
| publicationDate |
2020-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020084290-A1 |
| titleOfInvention |
T-cell receptor constant region 1 antibody or t-cell receptor constant region 2 antibody |
| abstract |
The present invention provides antibodies and polyclonal antibody preparations which bind the intracellular portion of either T-cell receptor constant region 2 (TRBC2) or T- cell receptor constant region 1 (TRBC1). The antibodies can be used to determine whether a T-cell malignancy clonally expresses TRBC1 or TRBC2.. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11385233-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022177889-A1 |
| priorityDate |
2018-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |